Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Borchmann

Showing results (211-220 of 252) with videos related to

Pageof 26
Sort By:
Blood Advances|January 9, 2026
Zamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 TrialHyatt Balke-Want, Philipp Gödel, Christoph Schmid, et al.
British Journal of Haematology|May 11, 2022
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysisJesko Momotow, Ina Bühnen, Karolin Trautmann-Grill, et al.
Blood|November 10, 2023
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNAJan-Michel Heger, Julia Mattlener, Jessica Schneider, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 26, 2023
Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapyJiaqi Fan, Anne Adams, Noëlle Sieg, et al.
Blood|October 28, 2020
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1Sarah Reinke, Paul J Bröckelmann, Ingram Iaccarino, et al.
The New England Journal of Medicine|December 4, 2018
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaStephen J Schuster, Michael R Bishop, Constantine S Tam, et al.
Blood Advances|February 12, 2020
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCLRakesh Awasthi, Lida Pacaud, Edward Waldron, et al.
The New England Journal of Medicine|September 8, 2010
Reduced treatment intensity in patients with early-stage Hodgkin's lymphomaAndreas Engert, Annette Plütschow, Hans Theodor Eich, et al.
Blood Advances|August 25, 2021
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphomaKaren Thudium Mueller, Stephan A Grupp, Shannon L Maude, et al.
Med (New York, N.Y.)|May 19, 2022
In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detectionSophia Sobesky, Laman Mammadova, Melita Cirillo, et al.
Pageof 26

Showing results (211-220 of 252) with videos related to

Sort By:
Pageof 26
Blood Advances|January 9, 2026
Zamtocabtagene Autoleucel in Relapsed/refractory B-NHL: 5-year Follow Up of a CD20/19 tandem CAR T Cell Phase 1 TrialHyatt Balke-Want, Philipp Gödel, Christoph Schmid, et al.
British Journal of Haematology|May 11, 2022
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma: A German Hodgkin Study Group multicentre real-world analysisJesko Momotow, Ina Bühnen, Karolin Trautmann-Grill, et al.
Blood|November 10, 2023
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNAJan-Michel Heger, Julia Mattlener, Jessica Schneider, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 26, 2023
Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapyJiaqi Fan, Anne Adams, Noëlle Sieg, et al.
Blood|October 28, 2020
Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1Sarah Reinke, Paul J Bröckelmann, Ingram Iaccarino, et al.
The New England Journal of Medicine|December 4, 2018
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell LymphomaStephen J Schuster, Michael R Bishop, Constantine S Tam, et al.
Blood Advances|February 12, 2020
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCLRakesh Awasthi, Lida Pacaud, Edward Waldron, et al.
The New England Journal of Medicine|September 8, 2010
Reduced treatment intensity in patients with early-stage Hodgkin's lymphomaAndreas Engert, Annette Plütschow, Hans Theodor Eich, et al.
Blood Advances|August 25, 2021
Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphomaKaren Thudium Mueller, Stephan A Grupp, Shannon L Maude, et al.
Med (New York, N.Y.)|May 19, 2022
In-depth cell-free DNA sequencing reveals genomic landscape of Hodgkin's lymphoma and facilitates ultrasensitive residual disease detectionSophia Sobesky, Laman Mammadova, Melita Cirillo, et al.
Pageof 26